Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma

Jong Sung Park, Yumin Oh, Yong Joo Park, Ogyi Park, Hoseong Yang, Stephanie Slania, Laura K. Hummers, Ami A. Shah, Hyoung Tae An, Jiyeon Jang, Maureen R. Horton, Joseph Shin, Harry C. Dietz, Eric Song, Dong Hee Na, Eun Ji Park, Kwang Meyung Kim, Kang Choon Lee, Viktor V. Roschke, Justin HanesMartin G. Pomper, Seulki Lee

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Scleroderma is an autoimmune rheumatic disorder accompanied by severe fibrosis in skin and other internal organs. During scleroderma progression, resident fibroblasts undergo activation and convert to α-smooth muscle actin (α-SMA) expressing myofibroblasts (MFBs) with increased capacity to synthesize collagens and fibrogenic components. Accordingly, MFBs are a major therapeutic target for fibrosis in scleroderma and treatment with blocking MFBs could produce anti-fibrotic effects. TLY012 is an engineered human TNF-related apoptosis-inducing ligand (TRAIL) which induces selective apoptosis in transformed cells expressing its cognate death receptors (DRs). Here we report that TLY012 selectively blocks activation of dermal fibroblasts and induces DR-mediated apoptosis in α-SMA+MFBs through upregulated DR5 during its activation. In vivo, TLY012 reverses established skin fibrosis to near-normal skin architecture in mouse models of scleroderma. Thus, the TRAIL pathway plays a critical role in tissue remodeling and targeting upregulated DR5 in α-SMA+ MFBs is a viable therapy for fibrosis in scleroderma.

Original languageEnglish
Article number1128
JournalNature communications
Volume10
Issue number1
DOIs
Publication statusPublished - 2019 Dec 1
Externally publishedYes

Fingerprint

TNF-Related Apoptosis-Inducing Ligand Receptors
fibrosis
Myofibroblasts
apoptosis
death
TNF-Related Apoptosis-Inducing Ligand
mice
Death Domain Receptors
Skin
Fibrosis
Chemical activation
Fibroblasts
spectral mixture analysis
fibroblasts
activation
Apoptosis
smooth muscle
ligands
Muscle
Actins

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma. / Park, Jong Sung; Oh, Yumin; Park, Yong Joo; Park, Ogyi; Yang, Hoseong; Slania, Stephanie; Hummers, Laura K.; Shah, Ami A.; An, Hyoung Tae; Jang, Jiyeon; Horton, Maureen R.; Shin, Joseph; Dietz, Harry C.; Song, Eric; Na, Dong Hee; Park, Eun Ji; Kim, Kwang Meyung; Lee, Kang Choon; Roschke, Viktor V.; Hanes, Justin; Pomper, Martin G.; Lee, Seulki.

In: Nature communications, Vol. 10, No. 1, 1128, 01.12.2019.

Research output: Contribution to journalArticle

Park, JS, Oh, Y, Park, YJ, Park, O, Yang, H, Slania, S, Hummers, LK, Shah, AA, An, HT, Jang, J, Horton, MR, Shin, J, Dietz, HC, Song, E, Na, DH, Park, EJ, Kim, KM, Lee, KC, Roschke, VV, Hanes, J, Pomper, MG & Lee, S 2019, 'Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma', Nature communications, vol. 10, no. 1, 1128. https://doi.org/10.1038/s41467-019-09101-4
Park, Jong Sung ; Oh, Yumin ; Park, Yong Joo ; Park, Ogyi ; Yang, Hoseong ; Slania, Stephanie ; Hummers, Laura K. ; Shah, Ami A. ; An, Hyoung Tae ; Jang, Jiyeon ; Horton, Maureen R. ; Shin, Joseph ; Dietz, Harry C. ; Song, Eric ; Na, Dong Hee ; Park, Eun Ji ; Kim, Kwang Meyung ; Lee, Kang Choon ; Roschke, Viktor V. ; Hanes, Justin ; Pomper, Martin G. ; Lee, Seulki. / Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma. In: Nature communications. 2019 ; Vol. 10, No. 1.
@article{f5b6a33d77be4bffa82a418537baa6b5,
title = "Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma",
abstract = "Scleroderma is an autoimmune rheumatic disorder accompanied by severe fibrosis in skin and other internal organs. During scleroderma progression, resident fibroblasts undergo activation and convert to α-smooth muscle actin (α-SMA) expressing myofibroblasts (MFBs) with increased capacity to synthesize collagens and fibrogenic components. Accordingly, MFBs are a major therapeutic target for fibrosis in scleroderma and treatment with blocking MFBs could produce anti-fibrotic effects. TLY012 is an engineered human TNF-related apoptosis-inducing ligand (TRAIL) which induces selective apoptosis in transformed cells expressing its cognate death receptors (DRs). Here we report that TLY012 selectively blocks activation of dermal fibroblasts and induces DR-mediated apoptosis in α-SMA+MFBs through upregulated DR5 during its activation. In vivo, TLY012 reverses established skin fibrosis to near-normal skin architecture in mouse models of scleroderma. Thus, the TRAIL pathway plays a critical role in tissue remodeling and targeting upregulated DR5 in α-SMA+ MFBs is a viable therapy for fibrosis in scleroderma.",
author = "Park, {Jong Sung} and Yumin Oh and Park, {Yong Joo} and Ogyi Park and Hoseong Yang and Stephanie Slania and Hummers, {Laura K.} and Shah, {Ami A.} and An, {Hyoung Tae} and Jiyeon Jang and Horton, {Maureen R.} and Joseph Shin and Dietz, {Harry C.} and Eric Song and Na, {Dong Hee} and Park, {Eun Ji} and Kim, {Kwang Meyung} and Lee, {Kang Choon} and Roschke, {Viktor V.} and Justin Hanes and Pomper, {Martin G.} and Seulki Lee",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41467-019-09101-4",
language = "English",
volume = "10",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma

AU - Park, Jong Sung

AU - Oh, Yumin

AU - Park, Yong Joo

AU - Park, Ogyi

AU - Yang, Hoseong

AU - Slania, Stephanie

AU - Hummers, Laura K.

AU - Shah, Ami A.

AU - An, Hyoung Tae

AU - Jang, Jiyeon

AU - Horton, Maureen R.

AU - Shin, Joseph

AU - Dietz, Harry C.

AU - Song, Eric

AU - Na, Dong Hee

AU - Park, Eun Ji

AU - Kim, Kwang Meyung

AU - Lee, Kang Choon

AU - Roschke, Viktor V.

AU - Hanes, Justin

AU - Pomper, Martin G.

AU - Lee, Seulki

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Scleroderma is an autoimmune rheumatic disorder accompanied by severe fibrosis in skin and other internal organs. During scleroderma progression, resident fibroblasts undergo activation and convert to α-smooth muscle actin (α-SMA) expressing myofibroblasts (MFBs) with increased capacity to synthesize collagens and fibrogenic components. Accordingly, MFBs are a major therapeutic target for fibrosis in scleroderma and treatment with blocking MFBs could produce anti-fibrotic effects. TLY012 is an engineered human TNF-related apoptosis-inducing ligand (TRAIL) which induces selective apoptosis in transformed cells expressing its cognate death receptors (DRs). Here we report that TLY012 selectively blocks activation of dermal fibroblasts and induces DR-mediated apoptosis in α-SMA+MFBs through upregulated DR5 during its activation. In vivo, TLY012 reverses established skin fibrosis to near-normal skin architecture in mouse models of scleroderma. Thus, the TRAIL pathway plays a critical role in tissue remodeling and targeting upregulated DR5 in α-SMA+ MFBs is a viable therapy for fibrosis in scleroderma.

AB - Scleroderma is an autoimmune rheumatic disorder accompanied by severe fibrosis in skin and other internal organs. During scleroderma progression, resident fibroblasts undergo activation and convert to α-smooth muscle actin (α-SMA) expressing myofibroblasts (MFBs) with increased capacity to synthesize collagens and fibrogenic components. Accordingly, MFBs are a major therapeutic target for fibrosis in scleroderma and treatment with blocking MFBs could produce anti-fibrotic effects. TLY012 is an engineered human TNF-related apoptosis-inducing ligand (TRAIL) which induces selective apoptosis in transformed cells expressing its cognate death receptors (DRs). Here we report that TLY012 selectively blocks activation of dermal fibroblasts and induces DR-mediated apoptosis in α-SMA+MFBs through upregulated DR5 during its activation. In vivo, TLY012 reverses established skin fibrosis to near-normal skin architecture in mouse models of scleroderma. Thus, the TRAIL pathway plays a critical role in tissue remodeling and targeting upregulated DR5 in α-SMA+ MFBs is a viable therapy for fibrosis in scleroderma.

UR - http://www.scopus.com/inward/record.url?scp=85062630746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062630746&partnerID=8YFLogxK

U2 - 10.1038/s41467-019-09101-4

DO - 10.1038/s41467-019-09101-4

M3 - Article

C2 - 30850660

AN - SCOPUS:85062630746

VL - 10

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 1128

ER -